Autologous Bone Marrow Transplantation in Relapsing Acute Leukemias

  • C. Annaloro
  • A. Della Volpe
  • R. Mozzana
  • A. Oriani
  • E. Pozzoli
  • D. Soligo
  • E. Tagliaferri
  • G. Lambertenghi Deliliers
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)

Abstract

Second complete remission (CR) can be achieved in more than 50% of relapsing patients with acute myelogenous (AML) and lymphoblastic leukemia (ALL); however, in spite of this relatively favourable CR rate, only a scant proportion of these patients experience long-term disease-free survival [1,2]. Various strategies have been designed in order to improve the above figure. Allogeneic (BMT) and autologous bone marrow transplantation (ABMT) appear to be therapeutic choices which could offer a significant advantage in terms of event free survival (EFS) [3,4].

Keywords

Toxicity Europe Leukemia Diarrhea Expense 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davis C. L., Rohatiner A.Z., Lim J., et al.: The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br. J. Haem. 1993, 83: 404–411.CrossRefGoogle Scholar
  2. 2.
    Hoelzer D.: Acute lymphoblastic leukemia — Progress in children, less in adults. New Engl. J. Med. 1993, 329: 1343–1344.PubMedCrossRefGoogle Scholar
  3. 3.
    Petersen F. B., Lynch M.H.E., Clift R.A., et al.: Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J. Clin. Onc. 1993, 11: 1353–1360.Google Scholar
  4. 4.
    Blume K.G., Kopecky K. J., Nenslee-Downey J.P., et al.: A prospective randomized comparison of Total Body Irradiation-Etoposide versus Busulfan-Cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: A Southwest Oncology Group Study. Blood 1993, 81: 2187–2193.PubMedGoogle Scholar
  5. 5.
    Hoelzer D., Gale R.B.: Acute lymphoblastic leukemia in adults: recent progress, future directions. Sem. Hemat. 1987, 24: 27–39.Google Scholar
  6. 6.
    Pavlovsky S., Fernandez I., Palau V., et al.: Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia. Ann. Oncol. 1991, 2: 441–442.PubMedGoogle Scholar
  7. 7.
    Linker C.A., Ries C.A., Damon L.A., et al.: Autologous bone marrow transplantation for acute myeloid leukemia using Busulfan plus Etoposide as a preparatory regimen. Blood 1993, 81: 311–318.PubMedGoogle Scholar
  8. 8.
    Foon K.A., Gale R.P.: Therapy of acute myelogenous leukemia. Blood Rev. 1992, 6: 15–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Wagner J.E., Vogelsang G.B., Zehnbauer B.A., et al.: Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Tranplant. 1992, 9: 205–209.Google Scholar
  10. 10.
    Vogler W.R.: Strategies in the treatment of acute myelogenous leukemia. Leukemia Research 1992, 16: 1141–1153.CrossRefGoogle Scholar
  11. 11.
    Gale R.P., Horowitz M., Butturini A.: Autotrans-plants in acute leukaemia. Br. J. Haematol. 1991, 78: 135–137.PubMedCrossRefGoogle Scholar
  12. 12.
    Vogler W.R., Berdel W.E., Olson A.C., et al.: Autologous bone marrow transplantation in acute leukemia with marrow purged with Alkyl-Lysophospholipid. Blood 1992, 80: 1423–1429.PubMedGoogle Scholar
  13. 13.
    Chao N.J., Stein A.S., Long G.D., et al.: Busulfan/Etoposide-Initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 1993, 81: 319–323.PubMedGoogle Scholar
  14. 14.
    Fyles G.M., Messner H.A., Lockwood G., et al.: Long-term results of bone marow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with high dose rate. Bone Marrow Transplant. 1991, 8: 453–463.PubMedGoogle Scholar
  15. 15.
    Schiffman K., Clift R., Appelbaum F.R., et al.: Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia. Bone Marrow Transplant. 1993, 11: 227–232.PubMedGoogle Scholar
  16. 16.
    Uckun F.M., Kersey J.H., Haake R., et al.: Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. N. Eng. J. Med. 1993, 329: 1296–1301.CrossRefGoogle Scholar
  17. 17.
    Robertson M.J., Soiffer R.J., Freedman A.S., et al.: Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 1992, 79: 2229–2236.PubMedGoogle Scholar
  18. 18.
    Rill D.R., Moen R.C., Buschle M., et al.: An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood 1992, 79: 2694–2700.PubMedGoogle Scholar
  19. 19.
    Gorin N.C., Labopin M., Meloni G., et al.: Autologous bone marow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 1991, 5: 896–904.PubMedGoogle Scholar
  20. 20.
    Lambertenghi-Deliliers G., Maiolo A.T., Annaloro C. et al.: Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non lymphoblastic leukemia. Eur. J. Clin. Oncol. 23: 1041–1045, 1987.CrossRefGoogle Scholar
  21. 21.
    Sallan S.E., Niemeyer CM., Billett A.L. et al: Autologous bone marrow transplantation for acute lymphoblastic leukemia. J. Clin. Oncol. 1989, 7: 1594–1601.PubMedGoogle Scholar
  22. 22.
    Burnett A.K.: Autologous BMT for ALL. Bone Marrow Transplant. 1989, 4 (Suppl 3): 79–80.PubMedGoogle Scholar
  23. 23.
    Annaloro C, Mozzana R., Butti C, et al.: Results of autologous bone marrow transplantation (ABMT) in 20 ALL patients after a 5-year follow-up. Ann. Hematol. 65 (Suppl 1): A30, 1992.Google Scholar
  24. 24.
    Coccia P.F., Strandjord S.E., Warkentin P.I., et al.: High-dose cytosine arabinoside and fractioned total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 1988, 71: 888–893.PubMedGoogle Scholar
  25. 25.
    Rivera G.K., Mauer A.M.: Controversies in the management of childhood acute lymphoblastic leukemia: treatment intensification, CNS leukemia, and prognostic factors. Semin Hematol 1987, 24: 12–26.PubMedGoogle Scholar
  26. 26.
    Bleyer W.A., Poplack D.G.: Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin. Oncol. 1985, 12: 131–148.PubMedGoogle Scholar
  27. 27.
    Gilmore M.J.M.L., Hamon M.D., Prentice H.G. et al.: Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant. 1991, 8: 19–26.PubMedGoogle Scholar
  28. 28.
    Simmonsson B., Burnett A.K., Prentice H.G., et al.: Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 1989, 3: 631–636.Google Scholar
  29. 29.
    Dicke K.A., Spinolo J.A.: High dose therapy and autologous bone marrow transplantation in acute leukemia: is purging necessary? Bone Marrow Transplant. 1989, 4 (suppl 1): 184–186.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • C. Annaloro
    • 1
  • A. Della Volpe
    • 1
  • R. Mozzana
    • 1
  • A. Oriani
    • 1
  • E. Pozzoli
    • 1
  • D. Soligo
    • 1
  • E. Tagliaferri
    • 1
  • G. Lambertenghi Deliliers
    • 1
  1. 1.Centro Trapianti di MidolloUniversity of MilanMilanoItaly

Personalised recommendations